Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression

NCT00887549 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00887549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00887549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
June 30, 2011
Enrollment
70 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer